Pharmafile Logo
Pharmafocus logo
Advanced Search

DPP-4

Showing 4 posts of 4 posts found.

Boehringer cheered by diabetes data

June 28, 2010
Research and Development Boehringer, DPP-4, diabetes, linagliptin

Boehringer Ingelheim has been cheered by phase III data showing its new oral once-daily type II diabetes tablet linagliptin significantly …

News

Five-year cardiovascular study planned for Onglyza

March 10, 2010
Research and Development, Sales and Marketing DPP-4, Onglyza, diabetes

Bristol-Myers Squibb and AstraZeneca are to embark on a five-year study of Onglyza in type II diabetes patients who may …

News
BIC_03 2

Boehringer prepares for diabetes launch

December 3, 2009
Medical Communications Boehringer, DPP-4, diabetes

Boehringer Ingelheim has hired the London arm of international PR agency Weber Shandwick to handle the UK launch of its …

News

AZ-BMS launch Onglyza in Europe

October 19, 2009
Sales and Marketing AZ, BMS, DPP-4, Onglyza, diabetes

 Bristol-Myers Squibb and AstraZeneca’s long-awaited type II diabetes drug Onglyza has been launched in the UK, its first European market.Designed …

News

Latest content

AbbVie invests €150m in new R&D facility in Germany

May 3, 2024

AstraZeneca shares positive interim results from phase 3 lymphoma trial

May 3, 2024

Merck shares data from phase 3 trial of Keytruda for gastric cancers

May 2, 2024

Verona Pharma to share phase 3 COPD trial data at ATS 2024

May 2, 2024

Beckman Coulter Life Sciences and Watchmaker Genomics enter collaboration

May 1, 2024